NRX PHARMACEUTICALS INC (NRXP) Stock Earnings & Estimates
USA - NASDAQ:NRXP - US6294442099 - Common Stock
2.87 USD
-0.1 (-3.37%)
2.88 USD
+0.01 (+0.35%)
Full estimates are only available for subscribed users, you can see which data is available below.
Subscribed users also see more surprise data, now it is restricted to 4 quarters.
Examples of complete estimate data are available for MSFT and AAPL.
Registered users have access to more data. Please register or login for additional estimates and surprises .
| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | N/A | N/A 395.09% | N/A 105.46% | N/A 330.97% | N/A 104.72% | N/A 1.68% | N/A 12.40% | N/A 0.37% | |||||||||
| EBITDA YoY % growth | N/A | N/A | N/A | N/A | -94.428M | -44.331M 53.05% | -27.582M 37.78% | -19.699M 28.58% | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | |
| EBIT YoY % growth | -134.5K | -1.007M -648.33% | -713.2K 29.14% | -907.4K -27.23% | -94.43M -10,306.66% | -44.335M 53.05% | -27.587M 37.78% | -19.704M 28.58% | N/A 74.96% | N/A 1,535.57% | N/A 251.56% | N/A 307.15% | N/A 107.89% | N/A 1.19% | N/A 12.19% | N/A 1.71% | |
| Operating Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | |
| EPS YoY % growth | N/A | N/A | N/A | N/A | N/A | N/A | -4.00 39.04% | -2.31 42.25% | N/A 92.05% | N/A 666.67% | N/A 167.16% | N/A | N/A | N/A | N/A | N/A |
All data in USD
| Q3 / 25 | Q4 / 25 | Q1 / 26 | Q2 / 26 | Q3 / 26 | Q4 / 26 | |
|---|---|---|---|---|---|---|
| EPS Q2Q % growth | -0.09 32.00% | 0.27 134.44% | 0.03 114.57% | 0.07 124.13% | 0.19 319.22% | 0.23 -14.10% |
| Revenue Q2Q % growth | 6.962M | 15.3M | 26.775M | 28.713M | 35.736M 413.30% | 36.655M 139.58% |
| EBITDA Q2Q % growth | -1.632M 45.92% | 3.57M 198.37% | 10.914M 391.27% | 11.016M 395.34% | N/A | N/A |
| EBIT Q2Q % growth | -1.448M 52.07% | 4.238M 216.62% | 6.477M 272.86% | 6.528M 275.01% | 16.508M 1,239.74% | 16.964M 300.28% |
All data in USD
| Period | Reported | Estimate | Difference | Surprise |
|---|---|---|---|---|
| Q2 2025 Q2Q % growth | -0.31 53.73% | -0.21 | -0.10 | -49.47% |
| Q1 2025 Q2Q % growth | -0.21 71.62% | -0.31 | 0.10 | 31.37% |
| Q4 2024 Q2Q % growth | -0.77 -54.00% | -0.32 | -0.45 | -138.39% |
| Q3 2024 Q2Q % growth | -0.13 81.43% | -0.65 | 0.52 | 80.09% |
| Q2 2024 Q2Q % growth | -0.67 44.17% | -0.71 | 0.04 | 5.49% |
| Q1 2024 Q2Q % growth | -0.74 53.75% | -0.56 | -0.18 | -31.91% |
| Q4 2023 Q2Q % growth | -0.50 68.75% | -0.71 | 0.21 | 29.97% |
| Q3 2023 Q2Q % growth | -0.70 50.00% | -1.16 | 0.46 | 39.44% |
| Q2 2023 Q2Q % growth | -1.20 -9.09% | -1.39 | 0.19 | 13.92% |
| Q1 2023 Q2Q % growth | -1.60 -661.90% | -1.43 | -0.17 | -12.04% |
| Q4 2022 Q2Q % growth | -1.60 -1,677.78% | -1.48 | -0.12 | -8.18% |
| Q3 2022 Q2Q % growth | -1.40 -250.00% | -1.43 | 0.03 | 1.96% |
| Q2 2022 Q2Q % growth | -1.10 -189.47% | -1.02 | -0.08 | -7.84% |
| Period | Reported | Estimate | Difference | Surprise |
|---|---|---|---|---|
| Q2 2025 Q2Q % growth | 1.53M | -1.53M | -100.00% | |
| Q1 2025 Q2Q % growth | 1.16M | -1.16M | -100.00% |
| Next Q (1 month) | Next Q (3 month) | Next Year (1 month) | Next Year (3 month) | |
|---|---|---|---|---|
| EPS | -4.01% | 3.7% | 0% | -5.88% |
| Revenue | -10.49% | -10.49% | -19.77% | -19.77% |